Our novel multiplex biochip revealed combinations of CEA + IL-8 and CEA + CRP to show the best screening performance for colon cancer with 47% sensitivity, for early carcinomas with 33% sensitivity, and adenomas with 18% sensitivity at an overall specificity of 86%. This evidence concerns the gene CRP and malignant colon neoplasm.